- Report
- August 2025
- 142 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- January 2026
- 193 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2026
- 283 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- January 2026
- 184 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 185 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- March 2025
- 180 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- April 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 213 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 158 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- August 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4379EUR$5,000USD£3,801GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4379EUR$5,000USD£3,801GBP
- Report
- June 2022
- 55 Pages
India
From €4379EUR$5,000USD£3,801GBP
- Report
- June 2021
- 197 Pages
Latin America
From €3503EUR$4,000USD£3,041GBP
- Report
- August 2023
- 1500 Pages
Global
From €7663EUR$8,750USD£6,651GBP
- Report
- October 2023
- 253 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- January 2025
- 183 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- January 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more